MedTrace Logo

A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

NCT07700992 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-07-14

No results posted yet for this study

Summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology

Conditions

  • Familial Pancreatic Cancer
  • Familial Pancreatic Carcinoma
  • Hereditary Pancreatic Cancer
  • Hereditary Pancreatitis
  • Pancreas Cancer
  • Pancreas Neoplasm
  • Pancreas Adenocarcinoma
  • Pancreas Cyst
  • Pancreatic Neoplasms
  • Intraductal Papillary Mucinous Neoplasm

Interventions

DIAGNOSTIC_TEST

PANXEON

A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples

Sponsors & Collaborators

  • Università Vita-Salute San Raffaele

    lead OTHER

Principal Investigators

  • Alessandro Mannucci, MD · Università Vita-Salute San Raffaele

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-03
Primary Completion
2031-12-31
Completion
2032-01-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07700992 on ClinicalTrials.gov